oral administration of Cassia seed (3.0g), once/day for 12 weeks

oral administration of Cassia seed placebo (3.0g), once/day (90% of starch and 10% of cassia obtusifolia) for 12 weeks

Schizophrenia

cassia seed tablet

Calo Psychiatric Center

Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia

the parameter of BMI in kg/m^2 for exploring the changes of body mass index (BMI) after cassia obtusifolia treatment

the parameter of systolic blood pressure and diastolic blood pressure after cassia obtusifolia treatment

the concentration of lipid profile, including total cholesterol, triglyceride, high denisty lipoprotein and low density lipoprotein after cassia obtusifolia treatment.

the parameter of meridian energy after cassia obtusifolia treatment

For-Wey Lung

superintendent

Total of 92 schizophrenia patients with obesity was divided randomly into: 1) control group, received oral administration of Cassia seed placebo (3.0g), once/day for 12 weeks continuously; 2) treatment group, received oral administration of Cassia seed (3.0g), once/day for 12 weeks continuously.

All participants are randomized into treatment or placebo group. Investigator also did not know who are in which group.

A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of cinnamomum cassia orally every 8 hours, for 90 days.

A group of 14 patients (7 women and 7 men) with DM2 without adequate control, treated with metformin 850mg daily, who will receive 1g of placebo (calcined magnesia) orally every 8 hours, for 90 days.

Diabetes Mellitus, Type 2

The sample size will be 28 patients, 14 men and 14 women.

The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.

Cinnamomum Cassia

The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.

Placebo (calcined magnesia)

Pubchem; 2017.Accessed at https://pubchem.ncbi.nlm.nih.gov on 15 June 2017.

Biomedical Unit Research 02, Specialties Hospital, Medical Unit of High Specialty, West National Medical Center, Mexican Social Security Institute.

Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated

Effect of Cinnamomum Cassia as an Enhancer of the Insulin Response of the Insulin-Like Growth Factor-1 and Metabolic Control in Patients With Type 2 Diabetes Mellitus Treated With Metformin Without Glycemic Control

Changes in the levels of the fasting glucose decrease and glycated hemoglobin

Changes in the levels of total cholesterol

Changes in the levels of systolic and diastolic blood pressure

All data resulting from the clinical investigation, except the personal identification of the subjects (name, address, telephone, etc.)

Sandra Ofelia Hernández González

Medical Research Associate C, Unit in Clinical Epidemiology, Specialities Hospital, Medical Unit of High Specialty; West National Medical Center, Mexican Institute of Social Security.

Coordinación de Investigación en Salud, Mexico

Controlled clinical trial, of two parallel groups, double blind, with random assignment and control group.
Process:
Visit 1 / Day -7: Period of scrutiny, study information, consent signature, clinical history, anthropometry, baseline laboratory tests.
Visit 2 / Day 0: Start the intervention period, simple random assignment for study groups, delivery of medication, general recommendations of diet and exercise.
Visit 3 / Day 30 - Visit 4 / Day 60: Adherence to treatment, taking laboratory tests, evaluation of adverse events, general recommendations of diet and exercise, general recommendations of diet and exercise will be evaluated.
Final Visit / Day 90 ± 7: Anthropometric measurements will be taken, laboratory tests will be taken, treatment adherence and adverse events will be evaluated, end of the intervention period.

Random assignment of groups and blinding:
All participants will be submitted to the selection of a sealed envelope which will have a numerical code previously defined by a third party for each intervention group.
The total number of envelopes required to complete the minimum number of participants (28) will be divided according to sex in two boxes, there will be 14 envelopes for men and 14 envelopes for women, with numerical codes that identify the bottle of intervention treatment that should receive the participant during the intervention period. They will be divided into 7 blinded codes for cinnamomum cassia group and 7 for placebo to complete the size of each subsample. Chance guarantees blinding, neither the participant nor the researcher will know the type of treatment. The database for the blinded statistical analysis will be completed. The blind man will be removed once the statistical analysis has been completed.

Randomized to cinnamon cassia 750 mg TID for 6 months. Assess HbA1c and CV risk profile

Randomized to placebo matching tablet TID for 6 months. Assess HbA1c and CV risk profile

Diabetes Mellitus

Cinnamon

placebo

The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus

Scott M. Chadderdon

Assistant Professor

Oregon Health and Science University

Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.

Type 2 Diabetes

Hypercholesterolemia

Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
2 capsules after the two largest meals of the day

Cinnamonforce

Placebo. 2 capsules after the two largest meals of the day

Placebo

Canadian College of Naturopathic Medicine

UHN - Toronto Western Hospital

The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark

The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark (Cinnamomum Verum and C. Aromaticum) (Cinnamonforce™) - Randomized Placebo-Controlled Clinical Trial

cassia/triglyceride

Therapeutic Effect of Cassia Seed in Obesity of Patients With Schizophrenia

Cinnamomum Cassia Effect on IGF1 and Metabolic Control in Patients With DM2 Without Glycemic Control Metformin Treated

The Effect of Cinnamon Cassia on Diabetes Control and Cardiometabolic Risk Factors in Adults With Type 2 Diabetes Mellitus

The Anti-Diabetic and Cholesterol-Lowering Effects of Cinnamon and Cassia Bark

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen